Ipsen reported a strong financial performance for FY 2025, achieving total sales of €3.68 billion, reflecting a growth of 10.9% at constant exchange rates (CER) and 8.1% as reported. Key growth drivers included Oncology (4.1%), Rare Disease (102.5%), and Neuroscience (9.7%). Core operating income rose by 16.7% to €1.29 billion, with a core operating margin of 35.2%. The company anticipates over 13% sales growth in 2026, supported by significant regulatory and clinical milestones, including five expected major announcements. Notably, Ipsen made strides in innovation, including the acquisition of ImCheck Therapeutics and ongoing advancements in their pipeline, indicating a strong commitment to developing new therapies. Furthermore, they reported improvements in sustainability initiatives, achieving a significant reduction in emissions and promoting gender parity in leadership.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.globenewswire.com/news-release/2026/02/12/3236839/0/en/ipsen-delivers-strong-results-in-2025-driven-by-solid-execution-across-all-therapeutic-areas-and-provides-2026-guidance.html
